[{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Phenobarbital Sodium","moa":"GABA-A receptor","graph1":"Neurology","graph2":"Phase III","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"10","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1R","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Levetiracetam","moa":"SV2A","graph1":"Neurology","graph2":"Approved FDF","graph3":"SPARC","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"SPARC \/ Tripoint Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"SPARC \/ Tripoint Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by SPARC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : SPARC’s phenobarbital sodium powder for injection is a benzyl alcohol and propylene glycol-free formulation intended for the treatment of seizures in neonates.

                          Product Name : Phenobarbital Sodium-Generic

                          Product Type : Controlled Substance

                          Upfront Cash : $10.0 million

                          September 11, 2022

                          Lead Product(s) : Phenobarbital Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          02

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and El...

                          Product Name : Elepsia

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 22, 2020

                          Lead Product(s) : Levetiracetam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Tripoint Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Peptide Therapy Summit
                          Not Confirmed
                          Peptide Therapy Summit
                          Not Confirmed

                          Details : Sun Pharma has been granted a worldwide licence for the development and commercialization of SCD-044, which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 cli...

                          Product Name : SCD-044

                          Product Type : Other Small Molecule

                          Upfront Cash : $20.0 million

                          May 29, 2020

                          Lead Product(s) : SCD-044

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : $145.0 million

                          Deal Type : Licensing Agreement

                          blank